Algiax announces results from phase 2a trial for neuropathic pain treatment - PharmaTimes Study shows AP-325 offers lasting pain relief without central side effects

#AlgiaxPharmaceuticals #SMiPain #painmanagement #nonopioids #neuropathicpain #AP325 #monotherapy #peripheralpostsurgicalneuropathicpain #painrelief #chronicneuropathicpain #allostericGABAAreceptormodulator #GABAAsignalling #neuropathicpainmanagement #painreduction
pharmatimes.com/news/algiax-...